Principal Investigator: Brian Mickey
Keywords: Substance Use , TMS Department: Psychiatry
IRB Number: 00130589
Specialty: Psychiatry
Sub Specialties: Addiction Psychiatry
Recruitment Status: Recruiting

Contact Information

Rebecca Jacobs

Brief Summary

The purpose of this study is to evaluate the feasibility of a study protocol and provide pilot data to support a future sham-controlled clinical trial of transcranial magnetic stimulation (TMS) therapy for people with methamphetamine use disorder (MAUD).

Aim 1: Characterize changes in craving, depressive symptoms, anxiety symptoms, sleep quality, quality of life, and methamphetamine (MA) or other stimulant use over 4 weeks of dual-target TMS and 8 weeks of subsequent follow-up.

Aim 2: Estimate changes in functional connectivity and metabolite levels in the brain and response inhibition and selective attention as measured by a flanker task in people with MAUD after 4 weeks of dual-target TMS.

Aim 3: Evaluate retention in the study to establish feasibility and tolerability of the protocol.

Inclusion Criteria

- Age 18 to 60 years

- Diagnosed with an active methamphetamine use disorder, with use within the past month

- Planning to engage in psychosocial treatment for methamphetamine use disorder during the study period

- Capacity to consent for treatment and research participation

- English-speaking

Exclusion Criteria

- History of seizure, active neurological disease, or use of medications that may increase seizure risk (e.g., clozapine, bupropion)

- Other contraindication to TMS or MRI (see attached screening forms)

- Clinically significant heart or kidney disease or hemodynamic instability

- Pregnancy or intent to become pregnant

- Active heavy alcohol use

- Bipolar disorder or schizophrenia-spectrum disorder

- Inability to complete the protocol due to travel, work, etc.